About Us

New panels in Hematology testing menu

Neutropenia panel for 26 genes and severe combined immunodeficiency panel for 44 genes are now available through Asper Biogene.

Updates in Dermatology testing menu

We have added new genes to the Oculocutaneous Albinism and Ichthyosis gene panels.

Hereditary ataxia testing menu

We have upgraded our hereditary ataxia testing menu. In addition to the comprehensive panel, repeat expansion analysis for SCA1, SCA2, SCA3 and SCA6 is also available. 

Antidepressants PGx test

Asper Biogene has launched a new pharmacogenetic test – Antidepressants PGx – for assessing metabolic response to antidepressant medications.

SNHL and Hypothyroidism and Thyroid Hormone Resistance panels.

New genes have been added to Sensorineural Hearing Loss and Hypothyroidism and Thyroid Hormone Resistance panels.

News in Asper Pharmacogenetics

Asper Pharmacogenetics testing menu has been updated with Contraceptives + HRT PGx test. Malignant hyperthermia panel now includes the STAC3 gene.

Company profile

Genetic testing company Asper Biotech has been acquired by Asper Biogene LLC and hereafter will be operating under the name of Asper Biogene. The deal was concluded in July 2017 to enhance the testing services and expand into new markets. The company is maintaining its focus on diagnostics for rare and common hereditary diseases.

Our testing menu has become one of the most comprehensive in the clinical diagnostics field. Starting with tests for eye diseases, we have broadened the testing scope, which now encompasses to neurological, cardiological, oncological, hematological etc. areas. Besides our best-known portfolio – Asper Ophthalmics seven new testing portfolios have been launched. As our aim is to provide flexible and customer-friendly services, our clients are always encouraged to ask for customized tests and testing solutions.

Our laboratory is an authorized medical laboratory, CLIA (#99D2046227), ISO 15189:2012, and ISO 9001:2015 certified. We are participating in the European Molecular Genetics Quality Network (EMQN) quality assessment schemes in order to deliver genetic services at the highest level of quality standards.

Our clients, including leading university hospitals, private clinics, commercial laboratories and research organisations are from more than 40 countries. Development and elaboration of new tests are continuous processes in our daily practice to meet the customers’ needs and provide testing services to more patients and healthcare providers. We are also offering custom-test development with complete workflow and full customer support.

Besides providing genetic diagnostic services, we are an appreciated scientific partner for many international R&D projects due to our innovation-driven approach and long-lasting experience. We have had successful collaboration with different funding agencies supporting R&D activities, which have led to technological improvements and moreover to state-of-the-art genetic tests. Our expertise is widely recognized by participation in numerous European-wide research projects where we have been incorporated as an essential partner.

About Asper Biotech

Asper Biotech was established in 1999 as a spin-off of the University of Tartu. Since then Asper Biotech quickly became a leading Estonian biotechnology exporter due to its extensive services and the quality of the results.